论文部分内容阅读
研究者测试了Pre-RELAX-AHF研究中234例心力衰竭患者基线和住院期间的肝功能指标,终点是第5天心力衰竭加重,60 d死亡率或再住院率和180 d死亡率。患者平均(70±10)岁,男性56%,73%患者NYHA心功能分级Ⅲ/Ⅳ级。肝功能指标常表现为ALT(12%)、AST(21%)、碱性磷酸酶(12%)和总胆红素(19%)升高,而血清白蛋白(25%)和总蛋白(9%)降低。住院期间指标变化很小。基线ALT和AST水平与180 d死亡率(HR每增加1倍=1.52,P=0.030和HR每增加1倍=1.97,P=0.013)和第5天心力衰竭加重(HR
The researchers tested 234 patients with heart failure in the Pre-RELAX-AHF study at baseline and during hospitalization for liver function, with endpoints of worsening heart failure, 60-day mortality or readmission and 180-day mortality at day 5. Patients were mean (70 ± 10) years, 56% of men and 73% of NYHA class III / IV patients. Indicators of liver function often show elevated ALT (12%), AST (21%), alkaline phosphatase (12%) and total bilirubin (19%), whereas serum albumin (25%) and total protein 9%) decrease. During hospitalization changes in indicators is small. Baseline ALT and AST levels were significantly associated with 180-day mortality (1-fold doubling HR = 1.52, P-0.030 and HR doubling = 1.97, P = 0.013)